Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Maine

Peptide legality · Maine · updated 2026-09-21

Are peptides legal in Maine?

Gray area

Maine leaves peptides in a legal gray zone: the state has no peptide-specific statute or Board of Pharmacy rule, so peptides are handled under Maine's general pharmacy and compounding law and the federal FDA framework.

Legal status overview

Maine leaves peptides in a legal gray zone, with no statute or Board of Pharmacy chapter that names BPC-157, TB-500, or peptides as a distinct regulated category. Instead, peptide products are governed by the Maine Pharmacy Act (Title 32, Chapter 117) and by the federal compounding standards under Sections 503A and 503B that the FDA administers. FDA-approved drugs and lawfully compounded preparations must be dispensed through a licensed Maine pharmacy on a valid prescription, and peptides sold for research use only for human consumption remain unauthorized. Because the rules track the federal framework, the status of individual peptides shifts as the FDA acts.

Key points

  • Maine has no statute or Board of Pharmacy rule naming peptides as a distinct category; peptide products fall under the Maine Pharmacy Act, Title 32, Chapter 117, and the federal compounding framework. [1]
  • Maine law LD 1315 restricts hospitals, nursing facilities, and ambulatory surgical centers from buying compounded drugs from unlicensed out-of-state entities, reinforcing that compounded peptides must come from state-licensed channels. [1]
  • BPC-157 and TB-500 sit in regulatory limbo nationwide: not FDA-approved, removed from the FDA Category 2 list in April 2026, and awaiting an FDA Pharmacy Compounding Advisory Committee review and any follow-on rulemaking. [3]
  • The FDA scheduled a Pharmacy Compounding Advisory Committee meeting for July 23 to 24, 2026 to review peptides including BPC-157, so their compounding status could change after that review. [2]
  • Compounded medications are not FDA-approved, are not a generic, and are not evaluated by the FDA for safety, effectiveness, or quality before they are dispensed. [4]
  • The GLP-1 class became difficult to compound as copies once the FDA declared the semaglutide shortage resolved in early 2025; FDA-approved brand products remain available on prescription through licensed Maine pharmacies. [4]
  • Peptides labeled research use only that are sold for human consumption are not authorized under Maine law and are exposed to federal FDA enforcement. [1]

Compound-by-compound status

BPC-157
Gray area
Not FDA-approved and no USP monograph. In Maine it is lawful only via a valid prescription through a licensed compounding pharmacy; removal from the FDA Category 2 list in April 2026 did not authorize compounding. Any compounded product is not FDA-approved, not a generic, and not evaluated by the FDA.
GLP-1 class (compounded semaglutide and tirzepatide, e.g. copies of Wegovy® (semaglutide), Ozempic® (semaglutide), Mounjaro® (tirzepatide), Zepbound® (tirzepatide))
Restricted
FDA-approved brand products are legal on prescription through licensed Maine pharmacies. Routine compounding of copies ended when the FDA resolved the shortage. Compounded GLP-1 medications are not FDA-approved, not a generic, and not evaluated by the FDA.
TB-500 (thymosin beta-4 fragment)
Gray area
No Maine-specific regulation; treated as an unapproved research peptide. Lawful only via valid prescription through a licensed pharmacy, and any compounded form is not FDA-approved, not a generic, and not evaluated by the FDA.
Growth hormone / somatropin
Restricted
Legal only as an FDA-approved prescription drug dispensed through a licensed Maine pharmacy. Federal law limits human growth hormone distribution to FDA-approved uses.

Frequently asked questions

Are peptides legal in Maine?

Maine has no peptide-specific law, so peptides sit in a gray zone governed by the Maine Pharmacy Act and the federal FDA framework. Lawful access is through a valid prescription filled by a licensed pharmacy. This is information, not medical or legal advice.

Can I buy BPC-157 online for personal use in Maine?

BPC-157 is not FDA-approved and has no USP monograph. Products sold research use only for human consumption are not authorized. It may be dispensed only via a valid prescription through a licensed compounding pharmacy.

Is compounded semaglutide still allowed in Maine?

Routine compounding of copies ended after the FDA resolved the shortage in early 2025. Compounded semaglutide is not FDA-approved, not a generic, and not evaluated by the FDA. FDA-approved products such as Wegovy® (semaglutide) can be prescribed.

Could the rules for BPC-157 change soon?

Yes. The FDA held a Pharmacy Compounding Advisory Committee meeting on July 23 to 24, 2026 to review peptides including BPC-157, and any change would still require follow-on FDA rulemaking.

Who oversees peptides in Maine?

The Maine Board of Pharmacy within the Department of Professional and Financial Regulation, operating within the FDA framework and Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

General information based on the sourced research above, not legal advice. For a specific situation in Maine, consult a licensed attorney familiar with pharmaceutical law.